The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes

Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target

(2012) S. Pascale et al.   BLOOD

Suboptimal Inhibition of Platelet Cyclooxygenase-1 by Aspirin in Metabolic Syndrome

(2012) James P. Smith et al.   HYPERTENSION

Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia

(2011) S. J. Barsam et al.   BLOOD

Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease

(2011) Davide Capodanno et al.   Circulation-Cardiovascular Interventions

Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications

(2011) Galia Spectre et al.   THROMBOSIS AND HAEMOSTASIS

Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes

(2010) Michael Pignone et al.   CIRCULATION

Effect of Obesity on the Pharmacokinetics of Drugs in Humans

(2010) Michael J. Hanley et al.   CLINICAL PHARMACOKINETICS

Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease

(2010) Marie Lordkipanidzé et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes

(2010) Faouzi Addad et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate

(2010) Laurent Bonello et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease

(2010) Adeline Vermillet et al.   THROMBOSIS AND HAEMOSTASIS

The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy

(2009) A. Dragani et al.   BLOOD

Association of Cyclooxygenase-1-Dependent and -Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization

(2009) Andrew L. Frelinger et al.   CIRCULATION

COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment

(2009) F. M. Pulcinelli et al.   EUROPEAN HEART JOURNAL

Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays

(2009) Francesca Santilli et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Antiplatelet Drugs

(2008) Carlo Patrono et al.   CHEST

Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 DiabetesA Randomized Controlled Trial

(2008) Hisao Ogawa   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION